Comment
Biologics for paediatric severe asthma: trick or TREAT?

https://doi.org/10.1016/S2213-2600(19)30045-1Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (27)

  • Design and analysis features used in small population and rare disease trials: A targeted review

    2022, Journal of Clinical Epidemiology
    Citation Excerpt :

    Rare disease trials face design challenges due to highly restricted recruitment. Participants to trials may also be limited if the focus is for a highly specialized sub-group; for example, a subset of asthmatic patients that do not respond to established therapeutic strategies [1] or trials where intervention was prohibitive, such as with expensive treatments or surgeries. With traditional parallel arm randomized controlled trials conducted in a frequentist framework, the required sample size is calculated through: desired power, significance level (type I error), and the minimal clinically important difference (MCID).

  • Difficult-to-Treat Asthma Management in School-Age Children

    2022, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    In children, in whom there is little evidence of an association between blood and airway eosinophilic inflammation, however, the optimal cutoff may be different and may affect efficacy. This discrepancy and extrapolation from adult studies highlights the need for childhood studies that both assess the efficacy of anti-IL5 therapies and define pediatric-specific biomarkers of response.34 An important role of sputum eosinophils is to enable a distinction between the clinical phenotypes of difficult-to-treat asthma and true STRA.

  • Prevention and Outpatient Treatment of Asthma Exacerbations in Children

    2021, Journal of Allergy and Clinical Immunology: In Practice
View all citing articles on Scopus
View full text